Keyword

KEAP1 mutation

Description: A genetic alteration in KEAP1, a regulator of the NRF2 antioxidant-response pathway, studied in cancer and associated with clinical outcomes.

Primary topic: Lung Cancer Treatments and Mutations (33%)

OpenAlex ID: keywords/keap1-mutation

Molecular mechanisms of the Keap1-Nrf2 pathway in stress response and cancer evolution

2011 · Keiko Taguchi, Hozumi Motohashi, et al. · Genes to Cells · 1,476

Loss of Keap1 Function Activates Nrf2 and Provides Advantages for Lung Cancer Cell Growth

2008 · Tsutomu Ohta, Kumiko Iijima, et al. · Cancer Research · 629

Genetic Alteration of Keap1 Confers Constitutive Nrf2 Activation and Resistance to Chemotherapy in Gallbladder Cancer

2008 · Tatsuhiro Shibata, Akiko Kokubu, et al. · Gastroenterology · 468

PDF

Nrf2 and Keap1 Abnormalities in Non–Small Cell Lung Carcinoma and Association with Clinicopathologic Features

2010 · Luisa M. Solis, Carmen Behrens, et al. · Clinical Cancer Research · 428

PDF

Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status

2021 · Biagio Ricciuti, Kathryn C. Arbour, et al. · Journal of Thoracic Oncology · 391

The Genomic Landscape of SMARCA4 Alterations and Associations with Outcomes in Patients with Lung Cancer

2020 · Adam J. Schoenfeld, Chai Bandlamudi, et al. · Clinical Cancer Research · 296

PDF

Keap1 Mutations and Nrf2 Pathway Activation in Epithelial Ovarian Cancer

2011 · Panagiotis A. Konstantinopoulos, Dimitrios Spentzos, et al. · Cancer Research · 271

PDF

Proteomic Analysis of Ubiquitin Ligase KEAP1 Reveals Associated Proteins That Inhibit NRF2 Ubiquitination

2013 · Bridgid E. Hast, Dennis Goldfarb, et al. · Cancer Research · 259

Chemical Proteomics Identifies Druggable Vulnerabilities in a Genetically Defined Cancer

2017 · Liron Bar-Peled, Esther K. Kemper, et al. · Cell · 257

PDF

Nrf2 protects against airway disorders

2009 · Hye-Youn Cho, Steven R. Kleeberger · Toxicology and Applied Pharmacology · 239

STK11 and KEAP1 mutations as prognostic biomarkers in an observational real-world lung adenocarcinoma cohort

2020 · Simon Papillon-Cavanagh, Parul Doshi, et al. · ESMO Open · 235

PDF

KEAP1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burden

2020 · D. Marinelli, M. Mazzotta, et al. · Annals of Oncology · 221

PDF

Squamous-cell carcinomas of the lung: emerging biology, controversies, and the promise of targeted therapy

2012 · Alexander Drilon, Natasha Rekhtman, et al. · The Lancet Oncology · 204

Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up

2016 · H Kadara, M Choi, et al. · Annals of Oncology · 200

PDF

Glutaminase inhibition impairs CD8 T cell activation in STK11-/Lkb1-deficient lung cancer

2022 · Sarah A. Best, Patrick M. Gubser, et al. · Cell Metabolism · 179

PDF

Clinical and Pathological Characteristics of KEAP1 - and NFE2L2 -Mutated Non–Small Cell Lung Carcinoma (NSCLC)

2018 · Rieke Frank, Matthias Scheffler, et al. · Clinical Cancer Research · 167

NRF2 activation induces NADH-reductive stress, providing a metabolic vulnerability in lung cancer

2023 · Tommy Weiss-Sadan, Maolin Ge, et al. · Cell Metabolism · 156

Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in KRAS- mutated non-small cell lung cancer with STK11 , KEAP1, or TP53 comutations: subgroup results from the phase III IMpower150 trial

2022 · Howard Jack West, Mark McCleland, et al. · Journal for ImmunoTherapy of Cancer · 155

PDF

KEAP1 mutation in lung adenocarcinoma promotes immune evasion and immunotherapy resistance

2023 · Anastasia-Maria Zavitsanou, Ray Pillai, et al. · Cell Reports · 153

Clinicopathologic Characteristics of BRG1-Deficient NSCLC

2020 · Ibiayi Dagogo-Jack, Alexa B. Schrock, et al. · Journal of Thoracic Oncology · 151

PDF

Activation of Oxidative Stress Response in Cancer Generates a Druggable Dependency on Exogenous Non-essential Amino Acids

2019 · Sarah E. LeBoeuf, Warren L. Wu, et al. · Cell Metabolism · 149

PDF

Integrative Radiogenomic Profiling of Squamous Cell Lung Cancer

2013 · Mohamed E. Abazeed, Drew J. Adams, et al. · Cancer Research · 125

A clinical drug library screen identifies clobetasol propionate as an NRF2 inhibitor with potential therapeutic efficacy in KEAP1 mutant lung cancer

2017 · E-J Choi, B-J Jung, et al. · Oncogene · 113

Mutation profiles in early-stage lung squamous cell carcinoma with clinical follow-up and correlation with markers of immune function

2016 · M. Choi, H. Kadara, et al. · Annals of Oncology · 111

STK11/LKB1 and KEAP1 mutations in non-small cell lung cancer: Prognostic rather than predictive?

2021 · Alessandro Di Federico, Andrea De Giglio, et al. · European Journal of Cancer · 105

Works count: 632

Citation count: 11,940